New Anti-Clotting Drug Asundexian Reduces Stroke Risk Without Increased Bleeding

A large international clinical trial has found that asundexian, an investigational anti-clotting medication, reduces stroke risk in people who recently experienced a non-cardioembolic stroke or transient ischemic attack without increasing bleeding complications. The drug specifically targets strokes caused by clots forming outside the heart, offering a potential alternative to existing stroke prevention treatments. Bleeding represents the most serious and feared complication of current anti-clotting therapies, making asundexian's safety profile particularly significant for stroke survivors at risk of recurrence.

Asundexian's efficacy in reducing stroke risk

• ▪Asundexian reduces the risk of stroke in people who recently experienced a stroke or transient ischemic attack caused by a clot forming outside of the heart
• ▪Asundexian is an investigational anti-clotting medication
• ▪Asundexian targets people who recently experienced a transient ischemic attack caused by non-cardioembolic clotting
• ▪A large international study found that asundexian reduces stroke risk in people who recently experienced non-cardioembolic stroke

Safety profile compared to existing treatments

• ▪Asundexian reduces stroke risk without increasing bleeding compared to existing stroke prevention treatments
• ▪Asundexian does not increase bleeding risk
• ▪Bleeding is the most serious and feared complication of existing stroke prevention treatments

Perspective of Stroke patients and at-risk individuals

• ▪Current stroke prevention treatments carry bleeding risks that patients fear as the most serious complication
• ▪Asundexian offers stroke survivors a treatment option that may avoid the dangerous bleeding side effects of existing medications

Perspective of Researchers and pharmaceutical developers

• ▪The large international trial of asundexian represents a significant advancement in anti-clotting drug development
• ▪Asundexian's mechanism targets non-cardioembolic stroke prevention, addressing a specific patient population with unmet medical needs